Journal Articles

  1. & The effectiveness and safety of proton beam radiation therapy in children with malignant central nervous system (CNS) tumours: protocol for a systematic review. Systematic Reviews 5(1)
  2. & Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1–3) Medulloblastoma – A safety/feasibility study. Radiotherapy and Oncology 111(1), 41-46.
  3. & MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathologica 123(4), 501-513.
  4. & Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: Results of a Children’s Cancer and Leukaemia Group study. European Journal of Cancer 47(9), 1389-1397.
  5. & Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables. Journal of Clinical Oncology 29(11), 1400-1407.
  6. & Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathologica 121(3), 381-396.
  7. & The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma. Journal of Neuro-Oncology 100(1), 81-88.
  8. & A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro-Oncology
  9. & Survival After Second Primary Neoplasms of the Brain or Spinal Cord in Survivors of Childhood Cancer: Results From the British Childhood Cancer Survivor Study. Journal of Clinical Oncology 27(34), 5781-5787.
  10. & Surveillance for Breast Cancer After Childhood Cancer. JAMA: The Journal of the American Medical Association 301(4), 435-436.
  11. & Promoting Collaboration between Adult and Paediatric Clinical Trial Groups. Clinical Oncology 20(9), 714-716.
  12. -Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. Journal of Clinical Oncology 23(31), 7951-7957.
  13. & Outcome for patients with metastatic (M2–3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. European Journal of Cancer 41(5), 727-734.
  14. & Impact of radiotherapy parameters on outcome in the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study of preradiotherapy chemotherapy for M0-M1 medulloblastoma. International Journal of Radiation Oncology*Biology*Physics 58(4), 1184-1193.
  15. Results of a Randomized Study of Preradiation Chemotherapy Versus Radiotherapy Alone for Nonmetastatic Medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. Journal of Clinical Oncology 21(8), 1581-1591.